Drug combo in AML: how antifungal affects cancer treatment levels
NCT ID NCT07254611
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how the antifungal drug posaconazole affects blood levels of the cancer drug venetoclax in 15 adults with acute myeloid leukemia (AML) who were also receiving a hypomethylating agent (azacitidine or decitabine). The goal was to see how many patients reached stable venetoclax levels by day 12 of treatment. The findings could help doctors adjust venetoclax doses to avoid toxicity while preserving its anti-leukemia effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
venetoclax and posaconazole
What this could lead to
If successful, this could help doctors safely adjust venetoclax doses when giving posaconazole, reducing toxicity while maintaining treatment effectiveness.
What could go wrong
This is a small, completed pharmacokinetic study (15 participants) that only measured drug levels, not treatment outcomes. Results may not apply to all patients or settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy